Wijith Munasinghe

1.6k citations

47 papers · 950 indexed · h-index 17

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
Hematology top 5%
- Multiple Myeloma Research and Treatments

Papers in ⓘ

Genetics 17
- Chronic Lymphocytic Leukemia Research 9
- Glioma Diagnosis and Treatment 7
Hematology 14
- Multiple Myeloma Research and Treatments 12

Co-authors: Hao Xiong (21 shared papers)Kyle D. Holen (19 shared papers)Ahmed Hamed Salem (9 shared papers)Andrew W. Roberts (10 shared papers)Jeremy A. Ross (11 shared papers)Shaji Kumar (8 shared papers)Peter Ansell (14 shared papers)Sari H. Enschede (6 shared papers)
Journals: Journal of Clinical Oncology (13 papers)Blood (7 papers)Neuro-Oncology (4 papers)Cancer Research (3 papers)Investigational New Drugs (2 papers)
Partner nations: United States Australia Netherlands

In The Last Decade

Wijith Munasinghe

46 papers receiving 940 citations

Peers

Countries citing papers authored by Wijith Munasinghe

Since Specialization

Citations

This map shows the geographic impact of Wijith Munasinghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wijith Munasinghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wijith Munasinghe more than expected).

Fields of papers citing papers by Wijith Munasinghe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wijith Munasinghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wijith Munasinghe. The network helps show where Wijith Munasinghe may publish in the future.

Co-authors

The 25 scholars most cited alongside Wijith Munasinghe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wijith Munasinghe Line = papers co-authored together Wijith Munasinghe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM Blood ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel Johansson, Sari H. Enschede, Jeremy A. Ross, Paulo Maciag, Maria Verdugo, Simon J. Harrison	2017	205
2	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma Neuro-Oncology ·David A. Reardon, Andrew B. Lassman, Martin J. van den Bent, Priya Kumthekar, Ryan Merrell, Andrew M. Scott, Lisa Fichtel, Erik P. Sulman, Erica Gomez, JuDee Fischer, Ho‐Jin Lee, Wijith Munasinghe, Hao Xiong, Helen Mandich, Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, Hui Gan	2016	86
3	Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies Gynecologic Oncology ·Heidi J. Gray, Katherine M. Bell‐McGuinn, Gini F. Fleming, Mihaela Cristea, Hao Xiong, Danielle Sullivan, Yan Luo, Mark D. McKee, Wijith Munasinghe, Lainie P. Martin	2018	58
4	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma Neuro-Oncology ·Hui Gan, David A. Reardon, Andrew B. Lassman, Ryan Merrell, Martin J. van den Bent, Nicholas Butowski, Zarnie Lwin, Helen Wheeler, Lisa Fichtel, Andrew M. Scott, Erica Gomez, JuDee Fischer, Helen Mandich, Hao Xiong, Ho‐Jin Lee, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, Priya Kumthekar	2017	57
5	Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study The Lancet. Gastroenterology & hepatology ·Brian G. Czito, Dustin A. Deming, Gayle Jameson, Mary F. Mulcahy, Houman Vaghefi, Matthew W. Dudley, Kyle D. Holen, Angela De Luca, Rajendar K. Mittapalli, Wijith Munasinghe, Lei He, John Zalcberg, Samuel Y. Ngan, Philip Komarnitsky, Michael Michael	2017	53
6	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma Blood Advances ·Luciano J. Costa, Faith E. Davies, Gregory Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan‐Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah Al Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji Kumar, Edward A. Stadtmauer	2021	53
7	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study Blood ·Shuo Ma, Danielle M. Brander, John F. Seymour, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Michael Y. Choi, Constantine S. Tam, Tanita Mason-Bright, Betty Prine, Wijith Munasinghe, Ming Zhu, Su Young Kim, Rod Humerickhouse, Andrew W. Roberts	2015	46
8	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Blood ·Andrew W. Roberts, Shuo Ma, Danielle M. Brander, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Constantine S. Tam, Tanita Mason-Bright, Nikita Rudersdorf, Lori A. Gressick, Jianning Yang, Wijith Munasinghe, Ming Zhu, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, John F. Seymour	2014	38
9	A phase 1 study of ABT-806 in subjects with advanced solid tumors Investigational New Drugs ·James M. Cleary, David A. Reardon, Nilofer S. Azad, Leena Gandhi, Geoffrey I. Shapiro, Jorge Chaves, Michelle Pedersen, Peter Ansell, William Ames, Hao Xiong, Wijith Munasinghe, M. Dudley, Edward B. Reilly, Kyle D. Holen, Rod Humerickhouse	2015	28
10	Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects Clinical Pharmacology in Drug Development ·TT Cheung, Ahmed Hamed Salem, Rajeev Menon, Wijith Munasinghe, Orlando F. Bueno, Suresh Agarwal	2017	23
11	Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies Investigational New Drugs ·Guillermo Garcia‐Manero, Raoul Tibes, Tapan M. Kadia, Hagop Kantarjian, Martha Arellano, Emily Knight, Hao Xiong, Qin Qin, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Daniel H. Albert, Brian Oliver, Mark D. McKee, Justin L. Ricker, H. Jean Khoury	2015	20
12	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results Blood ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, David E. Darden, Lura Morris, Jeremy A. Ross, Ahmed Hamed Salem, Wijith Munasinghe, Ming Zhu, Joel Johansson, Paulo Maciag, Sari H. Enschede, Maria Verdugo, Rod Humerickhouse, Simon J. Harrison	2015	19
13	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial British Journal of Cancer ·Michael L. Maitland, Sarina A. Piha‐Paul, Gerald S. Falchook, Razelle Kurzrock, Ly M. Nguyen, Linda Janisch, Sanja Karovic, Mark D. McKee, Elizabeth Hoening, Shekman Wong, Wijith Munasinghe, Joann P. Palma, Cherrie K. Donawho, Guinan Lian, Peter Ansell, Mark J. Ratain, David S. Hong	2018	18
14	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Blood ·Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Façon, Shaji Kumar, Cyrille Touzeau, Jaclyn Cordero, Jeremy A. Ross, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Joel Johansson, Paulo Maciag, Maria Verdugo, Simon J. Harrison	2016	18
15	Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). Journal of Clinical Oncology ·Hui Gan, Kyriakos P. Papadopoulos, Lisa Fichtel, Andrew B. Lassman, Ryan Merrell, Martin J. van den Bent, Priya Kumthekar, Andrew M. Scott, Michelle Pedersen, Erica Gomez, JuDee Fischer, William Ames, Hao Xiong, Ho-Jin Lee, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, Rose Lai, David A. Reardon	2015	17
16	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology ·Luciano J. Costa, Edward A. Stadtmauer, Gareth J. Morgan, Gregory Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Mehrdad Mobasher, Kevin J. Freise, Jeremy A. Ross, John C. Pesko, Wijith Munasinghe, Jaclyn Cordero, Lura Morris, Paulo Maciag, Orlando F. Bueno, Shaji Kumar	2018	17
17	Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies Clinical Pharmacokinetics ·Silpa Nuthalapati, Wijith Munasinghe, Vincent L. Giranda, Hao Xiong	2017	16
18	Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood ·Luciano J. Costa, Edward A. Stadtmauer, Gareth J. Morgan, Gregory Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Mehrdad Mobasher, Kevin J. Freise, Jeremy A. Ross, John C. Pesko, Wijith Munasinghe, Saketh Gudipati, Sarah R. Mudd, Orlando F. Bueno, Shaji Kumar	2018	16
19	A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). Journal of Clinical Oncology ·Hui Gan, Lisa Fichtel, Andrew B. Lassman, Ryan Merrell, Martin J. van den Bent, Priya Kumthekar, Andrew M. Scott, Michelle Pedersen, Erica Gomez, JuDee Fischer, William Ames, Hao Xiong, Matthew W. Dudley, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Kyle D. Holen, David A. Reardon	2014	16
20	A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806 Journal of Nuclear Medicine ·Hui Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D. Holen, Yumin Zhang, Marika Ciprotti, F.T. Lee, Wijith Munasinghe, JuDee Fischer, Peter Ansell, Gerard B. Fox, Hao Xiong, Edward B. Reilly, Rod Humerickhouse, Andrew M. Scott	2021	15

About Wijith Munasinghe

Wijith Munasinghe is a scholar working on Genetics, Hematology, Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 47 papers that have together received 950 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (12 papers), Cancer Treatment and Pharmacology (9 papers), Chronic Lymphocytic Leukemia Research (9 papers), Colorectal Cancer Treatments and Studies (8 papers), Protein Degradation and Inhibitors (8 papers), HER2/EGFR in Cancer Research (7 papers), Glioma Diagnosis and Treatment (7 papers) and PARP inhibition in cancer therapy (6 papers). The work is most often cited by research in Genetics (357 citations), Hematology (334 citations), Oncology (464 citations), Pathology and Forensic Medicine (140 citations) and Molecular Biology (438 citations). Wijith Munasinghe has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Hao Xiong, Kyle D. Holen, Ahmed Hamed Salem, Andrew W. Roberts, Jeremy A. Ross, Shaji Kumar, Peter Ansell, Sari H. Enschede, Paulo Maciag and Jaclyn Cordero. Their work appears in journals such as Journal of Clinical Oncology, Blood, Neuro-Oncology, Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact